Roemheld syndrome

Hyloris Pharmaceuticals Reports 2022 Half-Year Results and Provides Corporate Update

Retrieved on: 
Thursday, September 1, 2022
Quality, Patient, NDA, IC/BPS, Pharmacokinetics, Program, Pain, VWAP, IV, Extraction (chemistry), ACS, Exercise, Tranexamic acid, Roemheld syndrome, Physician, EUR, Review, Annual general meeting, Milrinone, Company, FDA, Population, Information, Group, CRL, Bleeding, HF, Risk, Marketing, Woman, Endpoint security, Atrial fibrillation, LVAD, Euronext, Medical device, Pharmaceutical industry, Security (finance), Sotalol

Hyloris will generate additional data on extractables and leachables from the packaging components to respond to the FDAs information request.

Key Points: 
  • Hyloris will generate additional data on extractables and leachables from the packaging components to respond to the FDAs information request.
  • Hyloris and its partnerhave completed the clinical phase of the study to assess the pharmacokinetics of this product candidate.
  • Hyloris has contracted with a manufacturing organization to produce registration batches in preparation for an NDA submission to the FDA.
  • On 22 June 2022 Hyloris increased its capital and share premium with 2.8 million through the exercise of 1.2 million outstanding transactions warrants.

Peptilogics Strengthens Leadership Team with Executive Appointments

Retrieved on: 
Wednesday, August 10, 2022
Health, Health Technology, Other Health, General Health, Pharmaceutical, Biotechnology, Dupilumab, Roemheld syndrome, Asthma, ACS, Risk, Johnson & Johnson, Mortality, Inflammation, Recurrence, Senior, Algorithm, HBM, Technology, Growth, Hospital, Cystic Fibrosis Foundation, Marketing, Patient, Therapy, Â, Founders Fund, Twitter, QIDP, Bacteria, Deep learning, Sanofi, DPM, Lead, Atopic dermatitis, MBA, Cystic fibrosis, Fast Track, LinkedIn, Hip, Cardiac arrest, Disease, Fine chemical, Pharmaceutical industry

Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced two executive appointments to strengthen and expand its leadership team.

Key Points: 
  • Peptilogics, a clinical stage biotech company engineering peptide therapeutic solutions for patients with life-threatening diseases, today announced two executive appointments to strengthen and expand its leadership team.
  • The addition of Dr. Deshpande to our executive team and the promotion of Dr. Pachuda reflects the growth of our organization and the necessary leadership to advance our pipeline and technology initiatives, said Jonathan Steckbeck, Ph.D., Founder and CEO of Peptilogics.
  • Dr. Deshpande will be responsible for the overall company strategy and business development at Peptilogics.
  • I am excited to work with this team to engineer peptide therapeutics that address unmet medical and access needs across the world.

Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors

Retrieved on: 
Wednesday, June 15, 2022
Biotechnology, Pharmaceutical, Health, Cardiology, Internal medicine, Parliamentary Information Technology Committee, Public health, Obesity, Cardiovascular disease, Cleveland Clinic, Science, Hospital of the University of Pennsylvania, Roemheld syndrome, Cardiology, Director, Research, Massachusetts Institute of Technology, VA Boston Healthcare System, LinkedIn, Heart failure, Harvard School of Dental Medicine, Bristol Myers Squibb, University, YouTube, Hospital, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Twitter, Cornell University, Patient, Board, Board of directors, BMY, Instagram, Multimedia, Cleveland, Diabetes, NYSE, Management, Pharmaceutical industry, Facebook, Brigham

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022.
  • View the full release here: https://www.businesswire.com/news/home/20220615006039/en/
    We are pleased to welcome Dr. Deepak L. Bhatt to our Board of Directors, said Giovanni Caforio , M.D., board chair and chief executive officer, Bristol Myers Squibb.
  • For more information about the Bristol Myers Squibb Board of Directors, click here .
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Coronary Stents Market to Reach US$ 25.7 Bn by 2028, TMR Report

Retrieved on: 
Monday, April 18, 2022
Ageing, Degenerative disease, Roemheld syndrome, Obesity, Medtronic, Population, Stent, AMG International, Restenosis, Myocardial infarction, CVD, TMR, CAGR, Patient, Coronary artery disease, Canton, Johnson & Johnson, Boston Scientific, Alloy, Safety, Prevalence, Thrombosis, Risk, ACS, Pharmaceutical industry

Advanced stenting technologies such as drug-eluting stents are growing in use in PCIs in order to boost the patient outcomes in treating coronary syndrome (ACS), thereby propelling the revenue generation of the coronary artery stents market.

Key Points: 
  • Advanced stenting technologies such as drug-eluting stents are growing in use in PCIs in order to boost the patient outcomes in treating coronary syndrome (ACS), thereby propelling the revenue generation of the coronary artery stents market.
  • The introduction of bioabsorbable polymer drug-eluting stent systems has unlocked a new avenue for med-tech companies in the coronary stents market.
  • This has led to the expansion of a number of models of stents, thus enriching the value chain of the coronary stents market.
  • For instance, the introduction of bioabsorbable polymer drug-eluting stents has spurred new revenue streams for companies in the coronary stents market.

Coronary Stents Market to Reach US$ 25.7 Bn by 2028, TMR Report

Retrieved on: 
Monday, April 18, 2022
Coronary heart disease, susceptibility to, 8, Ageing, Degenerative disease, Roemheld syndrome, Obesity, Medtronic, Population, Stent, AMG International, Restenosis, Myocardial infarction, TMR, CVD, CAGR, Patient, Coronary artery disease, Canton, Johnson & Johnson, Boston Scientific, Alloy, Safety, Prevalence, Thrombosis, Risk, ACS, Pharmaceutical industry

ALBANY, N.Y., April 18, 2022 /PRNewswire/ -- Transparency Market Research: Continuous advancements in stent designs and the materials have significantly increased the safety and efficacy profile of coronary stents used in percutaneous coronary interventions (PCIs). Over years, multiple generation of coronary stents have been introduced and gained regulatory approval which lowered the rate of stent-related infections notably preventing acute vascular occlusion and restenosis. The global coronary stents market to advance at CAGR of 12.9% during 2021–2028.

Key Points: 
  • Advanced stenting technologies such as drug-eluting stents are growing in use in PCIs in order to boost the patient outcomes in treating coronary syndrome (ACS), thereby propelling the revenue generation of the coronary artery stents market.
  • The introduction of bioabsorbable polymer drug-eluting stent systems has unlocked a new avenue for med-tech companies in the coronary stents market.
  • This has led to the expansion of a number of models of stents, thus enriching the value chain of the coronary stents market.
  • For instance, the introduction of bioabsorbable polymer drug-eluting stents has spurred new revenue streams for companies in the coronary stents market.

Eicosapentaenoic Acid (EPA) Combined with Widely Used Statins Significantly Reduced Lipid Oxidation in Model Membranes

Retrieved on: 
Friday, April 1, 2022
Risk, Lipid, NASDAQ, LDL, Research, Hospital, DC, Investor, Membrane, Endothelial dysfunction, LLC, Eicosapentaenoic acid, Stroke, Inflammation, American College, GLOBE, Degenerative disease, EPA, Roemheld syndrome, ATM, Professional corporation, Dietary supplement, Amarin Corporation

After 96 h, control (untreated) membranes underwent significant oxidation with lipid peroxide (LOOH) levels reaching 2049 286 M.

Key Points: 
  • After 96 h, control (untreated) membranes underwent significant oxidation with lipid peroxide (LOOH) levels reaching 2049 286 M.
    EPA was found to have significantly reduced lipid oxidation in a dose-dependent fashion in the absence and presence of either ATM or rosuva.
  • The combination of EPA/ATM and EPA/rosuva reduced lipid oxidation by 86 and 75%, respectively (p
  • The information that Amarin posts on these channels and websites could be deemed to be material information.
  • This list of channels may be updated from time to time on Amarins investor relations website and may include social media channels.

Cordis Names George Adams, MD as Chief Medical Officer

Retrieved on: 
Thursday, December 9, 2021
Medicine, MHS, Health, FACC, Moyamoya disease, Leadership, American Board of Commissioners for Foreign Missions, Patient, Roemheld syndrome, Internal medicine, MIAMI, Coronary artery disease, History, MD, American Board of Internal Medicine, Multimedia, STEMI, CLI, Solution, Cardiovascular disease, MBA, Management, Pharmaceutical industry

MIAMI LAKES, Fla., Dec. 9, 2021 /PRNewswire/ -- Cordis, a global cardiovascular technology company, today announced George Adams, MD, MHS, MBA, FACC, FSCAI as Chief Medical Officer, furthering the organization's mission to differentiate itself as a technological leader and value-based global medical device company.

Key Points: 
  • MIAMI LAKES, Fla., Dec. 9, 2021 /PRNewswire/ -- Cordis, a global cardiovascular technology company, today announced George Adams, MD, MHS, MBA, FACC, FSCAI as Chief Medical Officer, furthering the organization's mission to differentiate itself as a technological leader and value-based global medical device company.
  • "We are delighted to have Dr. Adams join our team as we continue to build the new Cordis," said CEO Shar Matin.
  • Dr. Adams comes to Cordis with a distinguished combination of clinical practice, medical research, and product development experience.
  • "It is with great honor and excitement that I join the Cordis team as Chief Medical Officer," said Dr. Adams.

Cordis Names George Adams, MD as Chief Medical Officer

Retrieved on: 
Thursday, December 9, 2021
Medicine, MHS, Health, FACC, Moyamoya disease, Leadership, American Board of Commissioners for Foreign Missions, Patient, Roemheld syndrome, Internal medicine, MIAMI, Coronary artery disease, History, MD, American Board of Internal Medicine, STEMI, CLI, Solution, Cardiovascular disease, MBA, Management, Pharmaceutical industry

MIAMI LAKES, Fla., Dec. 9, 2021 /PRNewswire/ -- Cordis, a global cardiovascular technology company, today announced George Adams, MD, MHS, MBA, FACC, FSCAI as Chief Medical Officer, furthering the organization's mission to differentiate itself as a technological leader and value-based global medical device company.

Key Points: 
  • MIAMI LAKES, Fla., Dec. 9, 2021 /PRNewswire/ -- Cordis, a global cardiovascular technology company, today announced George Adams, MD, MHS, MBA, FACC, FSCAI as Chief Medical Officer, furthering the organization's mission to differentiate itself as a technological leader and value-based global medical device company.
  • "We are delighted to have Dr. Adams join our team as we continue to build the new Cordis," said CEO Shar Matin.
  • Dr. Adams comes to Cordis with a distinguished combination of clinical practice, medical research, and product development experience.
  • "It is with great honor and excitement that I join the Cordis team as Chief Medical Officer," said Dr. Adams.

The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the ve

Retrieved on: 
Thursday, December 9, 2021
PMI, Myocardial infarction, Angiography, Research, Adenosine, Medical imaging, CAAS, FFR, Patient, Method, Carotid artery stenosis, Erasmus MC, Roemheld syndrome, FAST, ECRI, Pharmaceutical industry

vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.

Key Points: 
  • vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.
  • CAAS vFFR allows doing so without the need of invasive wires- that are part of the routine practice to measure pressure gradients (FFR) and adenosine.
  • The trial is funded by research grants from Pie Medical Imaging (Maastricht, the Netherlands) and Siemens Healthineers GmbH (Erlangen, Germany).
  • PMI and 3mensio Medical Imaging are part of the Esaote Group, leader in the biomedical equipment sector.

The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the ve

Retrieved on: 
Thursday, December 9, 2021
PMI, Myocardial infarction, Angiography, Research, Adenosine, Medical imaging, CAAS, FFR, Patient, Method, Carotid artery stenosis, Erasmus MC, Roemheld syndrome, FAST, ECRI, Pharmaceutical industry

vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.

Key Points: 
  • vFFR can assess whether a coronary artery narrowing is functionally severe and requires treatment.
  • CAAS vFFR allows doing so without the need of invasive wires- that are part of the routine practice to measure pressure gradients (FFR) and adenosine.
  • The trial is funded by research grants from Pie Medical Imaging (Maastricht, the Netherlands) and Siemens Healthineers GmbH (Erlangen, Germany).
  • PMI and 3mensio Medical Imaging are part of the Esaote Group, leader in the biomedical equipment sector.